{"id":1448,"date":"2022-02-13T12:27:56","date_gmt":"2022-02-13T20:27:56","guid":{"rendered":"https:\/\/info.pediatricsdirectory.com\/?p=1448"},"modified":"2023-12-02T15:47:06","modified_gmt":"2023-12-02T20:47:06","slug":"1448-2","status":"publish","type":"post","link":"https:\/\/pediatricscommunity.com\/info\/1448\/","title":{"rendered":""},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-3\">\n<div class=\"wp-block-column is-layout-flow\" style=\"flex-basis:33.33%\"><i class=\"fas fa-brain clinicaltrial\"><\/i>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow\" style=\"flex-basis:66.66%\">\n<h4 class=\"wp-block-heading\">OPEN CLINICAL STUDY \/ REGISTRY (France): Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes<\/h4>\n\n\n\n<p>Rare epilepsies as a whole account for 20-30% of epilepsies, but knowledge about prognostic factors is currently limited. This means that it is difficult to provide adequate information to families at diagnosis and during follow-up. Prognostic factors are also important for management as they can have an impact on the patient&#8217;s outcome (time to intervention, choice of one molecule over another, etc.). <\/p>\n\n\n\n<p>Finally, few treatments are currently available for these epilepsies. One of the limitations to the development of treatments is the lack of real life data as it is difficult to create reliable primary endpoints such as the rate of patients becoming seizure free naturally compared to a therapeutic intervention.<\/p>\n\n\n\n<p><strong>MORE INFO:<\/strong> <a href=\"https:\/\/beta.clinicaltrials.gov\/study\/NCT05126914\">ClinicalTrials.gov<\/a><\/p>\n<\/div>\n<\/div>\n<span class=\"tags-links\"><a href=\"https:\/\/pediatricscommunity.com\/info\/epidemiology\/\" rel=\"tag\">epidemiology<\/a><a href=\"https:\/\/pediatricscommunity.com\/info\/epilepsy\/\" rel=\"tag\">epilepsy<\/a><\/span>","protected":false},"excerpt":{"rendered":"<p>OPEN CLINICAL STUDY \/ REGISTRY (France): Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes Rare epilepsies as a whole account for 20-30% of epilepsies, but knowledge about prognostic factors is currently limited. This means that it is difficult to provide adequate information to families at diagnosis and during follow-up. Prognostic factors are also important for [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[359,52],"tags":[979,982],"_links":{"self":[{"href":"https:\/\/pediatricscommunity.com\/info\/wp-json\/wp\/v2\/posts\/1448"}],"collection":[{"href":"https:\/\/pediatricscommunity.com\/info\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pediatricscommunity.com\/info\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pediatricscommunity.com\/info\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/pediatricscommunity.com\/info\/wp-json\/wp\/v2\/comments?post=1448"}],"version-history":[{"count":1,"href":"https:\/\/pediatricscommunity.com\/info\/wp-json\/wp\/v2\/posts\/1448\/revisions"}],"predecessor-version":[{"id":6101,"href":"https:\/\/pediatricscommunity.com\/info\/wp-json\/wp\/v2\/posts\/1448\/revisions\/6101"}],"wp:attachment":[{"href":"https:\/\/pediatricscommunity.com\/info\/wp-json\/wp\/v2\/media?parent=1448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pediatricscommunity.com\/info\/wp-json\/wp\/v2\/categories?post=1448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pediatricscommunity.com\/info\/wp-json\/wp\/v2\/tags?post=1448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}